Erlotinib targeted therapy in patient with advanced lung adenocarcinoma

Abstract

Lung cancer is the most common cancer in men and the third most common type of cancer after breast and colon cancer in women. The prognosis for this cancer is unfavorable and die each year in Poland about 22.000 people. The introduction of targeted therapy represents a significant advance in the treatment of advanced lung cancer. It gives an opportunity to extend the time to disease progression and is associated with fewer side effects compared to the classic chemotherapy. The efficacy of this therapy in tumors without a mutation of this type is not satisfactory. We present a case of a patient with advanced adenocarcinoma of the lung, which was treated with erlotinib. This treatment allowed for the maintenance of stable disease for 31 months while maintaining a good quality of life and continue working.